Media Articles Related to LO Ovral (Norgestrel / Ethinyl Estradiol)
Research reveals more than half of young women who have abortions were using contraception when they fell pregnant
Source: Abortion News From Medical News Today [2014.04.30]
Reproductive health charity Marie Stopes UK has launched the findings of the first research in the UK into the contraceptive use of women aged 16-24 having one or more abortions.
Males' access to the morning after pill was limited by nearly three-quarters of pharmacies
Source: Sexual Health / STDs News From Medical News Today [2014.09.12]
Male shoppers in search of emergency contraception do not always have an easy time making these purchases and may be turned away at their local pharmacies.
Published Studies Related to LO Ovral (Norgestrel / Ethinyl Estradiol)
A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel. [2005.02]
OBJECTIVES: To evaluate the impact on lipid and carbohydrate variables of a combined one-third ethinyl estradiol (EE)/levonorgestrel (LNG) dose reduction in oral contraceptives... CONCLUSION: Similar effects on the lipid and carbohydrate profiles were found for both preparations. The balanced one-third EE dose reduction in this new oral contraceptive caused slightly lower, but insignificant, changes in the lipid and carbohydrate variables compared with the reference treatment.
Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial. [2005.02]
BACKGROUND: This trial was conducted to compare cycle control with vaginal ring a combined contraceptive vaginal ring, and a combined oral contraceptive (COC) delivering 30 mug ethinylestradiol (EE) and 150 mug levonorgestrel... CONCLUSIONS: Cycle control with vaginal ring was excellent and superior to that of a COC containing 30 mug EE.
A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms. [2005.01]
This open-label randomized study compared the effects of two combined oral contraceptives (OCs) containing 3 mg drospirenone (DRSP)/30 microg ethinyl estradiol (EE) with 150 microg levonorgestrel (LNG)/30 microg EE on the prevalence and changes from baseline of premenstrual symptoms after six cycles...
Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use. [2004.11]
We evaluated ovarian follicular development in women during compliant use of oral contraceptives (OC). Thirty-six healthy women received: [35 microg ethinyl estradiol (21)/180 microg norgestimate (7), 215 microg norgestimate (7), 250 microg norgestimate (7)]; [30 microg ethinyl estradiol (21)/150 microg desogestrel (21)]; or [20 microg ethinyl estradiol (21)/100 microg levonorgestrel (21)] for 3 consecutive 28-day cycles...
Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. [2004.06]
OBJECTIVES: Poor cycle control and tolerability can be reasons for irregular pill intake. This study compared the tolerability of two low-dose oral contraceptives and their effect on cycle control... CONCLUSIONS: 20EE/DSG provided better cycle control than 20EE/LNG with less treatment discontinuation due to unacceptable bleeding. There were no apparent differences between the two groups regarding tolerability and quality of life. There was less acne with 20EE/DSG. Copyright 2004 Elsevier Inc.
Clinical Trials Related to LO Ovral (Norgestrel / Ethinyl Estradiol)
Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOneï¿½ or Placebo. [Recruiting]
Effects of Administration of Fostamatinib on Blood Concentrations of an Oral Contraceptive in Healthy Female Subjects [Recruiting]
A crossover study to assess the effect of repeated doses of fostamatinib on the levels of
oral contraceptive (Microgynon® 30) in the blood of healthy female subjects. The study will
consist of a screening period of up to 35 days, followed by 2 treatment periods (28 days
each) of an oral contraceptive (Microgynon® 30) in the absence and presence of fostamatinib.
The study will also evaluate the safety and tolerability of fostamatinib in combination
with an oral contraceptive
Treatment of Menorrhagia in Women With Thrombocytopenia: Comparison of Platelet Transfusion Alone to Platelet Transfusion With Continuous Oral Contraceptive Pills [Recruiting]
This study will explore the role of oral contraceptive pills in managing uterine bleeding in
women who have low blood platelet counts as a result of aplastic anemia. Oral contraceptive
pills have been shown to be effective in managing uterine bleeding in healthy women, but the
effects have not been thoroughly studied in women who have low platelet counts. The purpose
of the study is to determine whether oral contraceptive pills are a useful complement to
platelet transfusions in women with aplastic anemia and uterine bleeding.
Volunteers for this study must be women between 12 and 55 years of age who have been
diagnosed with aplastic anemia (with a platelet count of less than 50,000/microl) and
currently have active uterine bleeding. Candidates must not be pregnant or breastfeeding,
must have a uterus and at least one functioning ovary, and must be willing to use
nonhormonal methods of birth control (such as condoms or a diaphragm) for the duration of
the study. On the first visit, candidates will be screened with a complete medical history
(including obstetric and gynecological history) and will undergo a physical examination, a
pelvic exam and a pelvic ultrasound. Blood and urine samples will also be taken on this
The study will last approximately two weeks. Participants will be asked to monitor their
medication doses and severity of bleeding during the course of the study. After the first
visit, participants will be separated into two randomized groups and will receive either one
tablet of oral contraceptive or a placebo twice daily, to be taken 12 hours apart at the
same times each day. Participants will also receive platelet transfusions as needed to
ensure that their platelet counts remain over 20,000/microl. After seven days, researchers
will assess participants' uterine bleeding and all participants will be given oral
contraceptives in the second week of the study. Participants whose bleeding has decreased
will receive only one tablet; participants who still have moderate to severe uterine
bleeding will receive two tablets. A final assessment will be performed on day 14 of the
Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy [Not yet recruiting]
This study will examine whether the drug cetrorelex acetate (Cetrotide[Registed Trademark])
can protect ovarian function in women undergoing chemotherapy. Some cancer treatments are
known to cause a change in women's periods or to cause menstruation to stop completely, so
that they cannot become pregnant. Cetrorelex acetate has been used for many years to lower
hormone levels and stop periods in patients undergoing in vitro fertilization treatments.
This study will see if making the ovaries inactive may protect them from being affected by
certain cancer drugs, and thus preserve fertility.
Women up to age 21who have begun menstruating, who have their uterus and at least one
functioning ovary, and who are undergoing chemotherapy with cyclophosphamide, busulfan,
nitrogen mustard or L-phenalanin mustard may be eligible for this study.
Participants undergo the following procedures during this 24-month study:
- Medical history, physical examination and blood and urine tests
- Questionnaire about quality of life, menstrual periods, vaginal bleeding and desire for
- 3D ultrasound of abdomen
- DEXA scan to evaluate bone density
Assignment to treatment with:
- Lo ovral (contraceptive pill to prevent pregnancy and control menstrual periods) alone,
- Lo ovral and the study drug cetrorelex acetate, given as an injection under the skin
once a day for six menstrual cycles
- Transvaginal 3D ultrasound to monitor changes in the ovary - after 6 months of
cetrorelex acetate injections
- DEXA scan - after 6 months of cetrorelex acetate injections
- Blood tests for safety monitoring, pregnancy testing, endocrine tests and research uses
- every 3 months during first year, every 6 months during second year
- Questionnaire to monitor changes and quality of life - every 3 months during first
year, every 6 months during second year.